Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • Research Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET National Action Plan
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Bequests
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » News » ANZSNM Annual Scientific Meeting 21-23 May 2021

ANZSNM Annual Scientific Meeting 21-23 May 2021

  • May 21, 2021

“Unlocking the Potential of Nuclear Medicine” ANZSNM Annual Scientific Meeting 21 – 23 May 2021

This conference was a hybrid event with face-to-face sites in each state in Australia and virtual presentations, including International guest speakers. Simone and Meredith submitted a Poster – “Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumour (NET) Patients (SCAN) –Australia and New Zealand (Oceania) vs Global Diagnosis of NETs”.

This was accepted, with Meredith presenting an e-presentation overview of the SCAN Oceania Data. SCAN, a survey conducted by the International Neuroendocrine Cancer Alliance (INCA) looked at access across the board to different treatments, diagnostics and also issues with early diagnosis. We are heartened to see that access in Australia to vital Nuclear Medicine including PET scans and PRRT is high and so too is the experience of our specialists. 

Meredith attended (in person) the conference at Rydges World Square Sydney. The day commenced with the CEO, Shaun Jenkinson, of the Australian Nuclear Science and Technology Organisation (ANSTO) updating the audience about ANSTO activities, quality processes and improvements and future directions in supply and development. It was a wonderful opportunity to network and work together.

Other highlights of the conference included:

“Experience with COVID-19 in UK”, Prof John Buscombe, British Nuclear Medicine Society, UK

This was a really interesting presentation explaining the management of COVID in the UK and the utilisation of staff, PPE and also the importance of Australian Health Care Professionals in the UK which was of enormous benefit to the UK hospitals staffing. Australians could not leave due to closed borders in Australia and so their work visas were extended and enabled adequate levels of staff to be available.

On day 2 Plenary 1 was Droplet Radiochemistry: new approaches for efficient radiopharmaceutical development and production by Prof Michael van Dam from University of California, Los Angeles. This highlighted the development of equipment to enable de-centralised production – the scale of the equipment is smaller than a regular takeaway coffee cup!

Other sessions were Breast Cancer Imaging modalities, Infection and Inflammation which was a Technologist Syposium and included the impact of COVID on universities and training and also administration of local anaesthetic for sentinel lymphoscintigraphy which significantly reduces pain without reducing detection of lymph nodes.

Click below for the INCA SCAN – Oceania V Global poster and view Merediths overview below.

https://neuroendocrine.org.au/wp-content/uploads/2021/05/poster-mover.mp4
Click here for poster

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

5HIAA Urine Collection Instructions for Patients

June 23, 2022

Donor Report 2021/2022

June 21, 2022

Cancer Nurses Society of Australia 24th Annual Congress

June 18, 2022

The Future of Precision Oncology in Nuclear Medicine – Report

June 16, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousBioPharmaDispatch 2021
NextPatient perspectives, from diagnosis through treatments and beyond.Next

Related Posts

5HIAA Urine Collection Instructions for Patients

Your doctor may order you to do a 5HIAA 24 hour urine test. Please click below to see the downloadable instruction sheet. Previously there were

Donor Report 2021/2022

It is with heartfelt gratitude that we thank our kind donors who enable us to continue to do what we do. We encourage you to

Cancer Nurses Society of Australia 24th Annual Congress

The 24th Cancer Nurses Society of Australia’s  (CNSA) Annual Congress took place at Brisbane Convention Centre Thursday 16 June to Saturday 18 June 2022. The

The Future of Precision Oncology in Nuclear Medicine – Report

Theranostics refers to a combined therapy and diagnostics approach to patient treatment. It involves the use of a diagnostic drug to first identify and label

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies
Menu
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • Research Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
Menu
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
Menu
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
Menu
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative